IMMUNOVANT INC (IMVT)
Health Care · Clinical-stage immunology / FcRn inhibitor development · NASDAQ
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by pathogenic IgG antibodies.
What IMMUNOVANT INC does
Immunovant is a clinical-stage immunology company dedicated to developing IMVT-1402 (imeroprubart), an inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. The company believes FcRn inhibition has broad therapeutic potential across multiple therapeutic areas including endocrinology, neurology, rheumatology, and dermatology. The company is also managing the transition away from batoclimab (IMVT-1401) following a strategic decision to discontinue that program and negotiate potential return of rights to HanAll Biopharma.
Themes: ["Autoimmune disease treatment","FcRn inhibition / pathogenic IgG reduction","Immunology","Clinical-stage biotech","Endocrinology, neurology, rheumatology, dermatology applications"]
Fundamentals
- Price$41.09 as of 2026-07-09 close
- Market cap$8.4B as of 2026-07-10
- 1-year return+137.7% as of 2026-07-09 close
- ROE-68.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.81 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial timing, progress, costs and results are uncertain, particularly for IMVT-1402; regulatory approval is not guaranteed and feedback from regulatory authorities may affect study design","Dependence on third parties for R&D, clinical trials, manufacturing and other activities creates execution risk and supply chain vulnerabilities","Company is pre-revenue and burning cash to fund ongoing losses; future financing needs are substantial and success depends on ability to achieve regulatory approval and successful commercialization of product candidates"]
Competitors & peers
- Roche (RHHBY) — FcRn inhibitor programs
- Regeneron Pharmaceuticals (REGN) — autoimmune/immunology focus
- Amgen (AMGN) — autoimmune disease treatments
- Janssen Pharmaceuticals — autoimmune disease treatments
- Sanofi (SNYNF) — immunology and autoimmune programs
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.